Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will present at the Evercore ISI 4th Annual HealthCONx Healthcare Conference on November 30, 2021, at 12:10 PM EST. Investors can access the live webcast on the company's investor relations website, with a replay available for 90 days. Founded over 60 years ago, Waters is a leader in specialty measurement, including chromatography and mass spectrometry, with operations in 35 countries and products available in over 100 countries.
Summary not available.
Waters Corporation (NYSE: WAT) reported third quarter 2021 sales of $659 million, an 11% increase from $594 million in Q3 2020. GAAP EPS rose to $2.60, up from $2.03 year-over-year. Non-GAAP EPS was $2.66, reflecting a 23% increase. Key growth drivers included a 16% rise in pharmaceutical sales and 9% in industrial markets. The company anticipates full-year 2021 sales growth of 15%-16% and non-GAAP EPS between $10.94 and $11.04. Waters also experienced strong recurring revenue growth of 11% in Q3, alongside a 10% increase in instrument sales.
Waters Corporation (NYSE: WAT) and Sartorius (DAX: SRT:GR) have announced a partnership to enhance biopharmaceutical process development. Their collaboration integrates the Waters BioAccord LC-MS System with Sartorius’ Ambr multi-parallel bioreactor systems, enabling faster access to critical quality data. This integration can reduce analysis time from several weeks to just two days, aiding scientists in clone selection and process optimization. The initiative aims to meet the growing demand for upstream analytical data in the rapidly expanding biopharmaceutical market, projected to grow at a ~10% CAGR until 2025.
Waters Corporation (NYSE:WAT) and the University of Delaware have announced a multi-year partnership aimed at enhancing analytical solutions for the biopharmaceutical industry. The collaboration will take place at Immerse Delaware, a new research lab located on the university's STAR campus, focusing on improving drug quality, yields, and manufacturing efficiency. Through this partnership, Waters and university researchers will work on projects leveraging LC-MS technologies to address significant challenges in bioprocessing, ultimately aiming to accelerate the delivery of high-quality medicines.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q3 2021 financial results on November 2, 2021, at 8:00 a.m. eastern time. Investors can access the webcast via the Waters investor relations website. A replay will be available until November 16, 2021, at midnight eastern time. Waters has over 60 years of experience in chromatography and mass spectrometry, employing more than 7,400 staff across 35 countries. The company continues to lead in specialty measurement solutions for life, materials, and food sciences.
Waters Corporation (NYSE:WAT) has appointed John M. Ballbach to its Board of Directors, effective October 5, 2021. This appointment follows the retirement of Dr. Michael J. Berendt, who served on the board for over two decades. Ballbach brings extensive experience in the life sciences tools sector, with a robust background in M&A and operational excellence. His appointment comes at a pivotal time for Waters as the company aims to enhance its growth and value creation strategies.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, a new LC-MS system aimed at enhancing multi-attribute monitoring of biotherapeutics. This system significantly improves analyte recovery and assay reproducibility, addressing challenges posed by analyte-to-metal interactions. Expected to facilitate quicker access to mass spectrometry data, the system aims to lower costs and expedite the delivery of medicines to patients. Customer shipments are set to commence at the month’s end.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, an advanced LC-MS system designed for improved monitoring of biotherapeutics. This system significantly enhances analyte recovery and assay reproducibility, allowing faster access to critical data about biologics. Key features include MaxPeak HPS technology, which eliminates analyte-to-metal interactions, resulting in up to 300% increase in sensitivity for glycan profiling. Shipments are expected to begin soon, which may help accelerate the delivery of essential medicines to patients.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will present at the Bank of America Global Healthcare Conference on September 16, 2021, at 3:55 PM BST (10:55 AM Eastern Time). Investors can access the live webcast on Waters' investor relations website. Waters, a leader in specialty measurement, has over 7,400 employees and operates in 35 countries, with products available in more than 100 countries.